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Summary To investigate the cell biological function of PU.1, a member of the Ets family of transcription factors, a vector capable of
expressing the protein was transfected into HT1080 human fibrosarcoma cells. Exogenous expression of PU.1 in HT1080 cells reduced
colony-forming efficiency but stimulated cell migration in soft agar, although it did not affect cell growth in adherent culture. Expression of the
urokinase-type plasminogen activator (uPA) mRNA, which is known to be correlated with cell migration and invasion, was enhanced in PU. 1
transfectants compared with mock transfectants. Run-on analysis demonstrated that uPA transcription was unaffected by PU.1, suggesting
that this enhancement mainly occurs at a post-transcriptional level. On the other hand, treatment of HT1080 cells with the synthetic
glucocorticoid dexamethasone (DEX; 10-7 M) significantly reduced uPA gene expression at a transcriptional level. Furthermore, DEX inhibited
cell migration in soft agar without affecting cell growth. These negative effects of DEX on uPA expression and cell migration were alleviated
by the expression of PU.1 in HT1080 cells, whereas expression of the N-ras oncogene, which is responsible for maintenance of the
transformed phenotypes in HT1080 cells, was unaffected by PU.1 expression or DEX treatment in the cells. Our results suggest that
expression of PU.1 can stimulate uPA gene expression at the post-transcriptional level, which may subsequently lead to activation of cell
motility and/or reduced cell-cell adhesion, but reduces anchorage-independent growth of HT1080 cells.
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PU. 1 is a member of the Ets family of transcription factors and is
expressed in B cells and macrophages (Klemsz et al, 1990). The
protein activates several promoters and enhancers ofvarious genes
in B-cell and myelomonocytic cell lineages (Moreau-Gachelin,
1994; Simon et al, 1996). PU.l is not expressed in mature T cells
or erythroid cells. In Friend virus-induced mouse
erythroleukaemia (MEL) cells, however, expression of the
PU.I/Spi-1 gene is activated by proviral insertion of spleen focus-
forming virus (SFFV) (Moreau-Gachelin et al, 1988; Paul et al,
1991). It has been proposed that the enhanced and constitutive
expression of the PU. I gene in erythroid cells exerts a role in the
neoplastic process by blocking differentiation of erythroblasts
(Shuetze et al, 1993; Moreau-Gachelin et al, 1996). We previously
reported that overexpression ofthe PU.I gene in MEL cells blocks
cell differentiation, inhibits cell growth and induces apoptosis in
the presence of dimethylsulphoxide (DMSO) (Yamada et al,
1997). These results suggest that the gene exerts versatile effects
on transformed phenotypes.
In this report, we attempted to investigate the possible effect of
PU. 1 on the transformed phenotypes other than in haematopoietic
cells. We ectopically expressed the PU.] gene in a human fibro-
sarcoma cell line, HT1080, harbouring the activated N-ras gene
and observed alterations ofthe biological phenotypes.
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MATERIALS AND METHODS
Plasmid construction
A 1.2-kb mouse PU.] full-length cDNA (Klemsz et al, 1990),
kindly donated by Dr D. Kabat, was cloned into an eukaryotic
expression vector, pLRNL (Hung et al, 1988), downstream of the
MuLV promoter.
Cell culture and transfection
Two subclones, NM-1 and cl-2, were isolated from a human
fibrosarcoma cell line, HT1080, purchased from the American
Type Culture Collection. Cells were maintained in Dulbecco's
modified Eagle minimum essential medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). The cells were trans-
fected with the PU. I expression vector using Lipofectin reagent
(Gibco/BRL) and transfectants were selected in the medium
containing G418 (1 mg ml-').
Western blot analysis
Proteins were electrophoresed in a 12% sodium dodecyl sulphate
(SDS)-polyacrylamide gel and transferred electrophoretically
on to a nylon membrane (Immobilon; Millipore). The blot
was probed with anti-PU. 1 polyclonal antibody (Santa Cruz).
Chemiluminescent signals of the immunoreactive proteins were
visualized on an X-ray film using the ECL kit (Amersham).
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Figure 1 Western blot analysis of PU.1 protein in HT1080 NM-1 cells
transfected with an expression vector of mouse PU.1 full-length cDNA. PU.1
migrates at 34 kDa (arrow)
Table 1 Growth properties of HT1080 NM-1 cells transfected with PU.1
expression vector
Cells PU.1 protein Doubling Colony
levels time (h) formation (%)a
Controls
HT1080 NM-1 - 15.0 47.7 + 6.7
Vector - 16.0 35.5 +5.7
PU.1 transfectants
NMPU.1-7 ++ 15.0 17.1 ± 1.4
NMPU.1-8-1 + 15.0 22.5 + 4.5
NMPU.1-11-L +++ 15.0 17.7 ± 3.3
NMPU.1-26 + 15.0 20.7 ± 6.3
a2.5 x 103 cells per plate were seeded. Colony formation was scored into
duplicated dishes 3 weeks after the seeding.
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Figure 2 Morphology of colonies at the early stage of PU. 1 transfectants in
soft agar. Parental HT1080 MN-1 cells (A and C) and PU. 1-transfectant
NMPU.1-7 cells (B and D) were cultured in soft agar either in the absence (A
and B) or presence (C and D) of 10-7 M DEX as described in Materials and
methods
was visualized by film autoradiography and band intensity was
measured by a densitometer (GS-700, Bio-Rad).
Cell growth analysis
A total of x 104 cells were cultured in 5 ml of culture medium in
6-cm plastic dishes. Cell numbers were counted every 24 h and
doubling times were calculated by means of cell numbers from
triplicated samples in the exponentially growing stage ofcells.
Soft agar colony-formation assay
A total of2.5 x 10 cells were plated in 0.3% Noble agar (Difco) in
DMEM with 10% FBS in the presence or absence of 10-7 M of
DEX. After 3 weeks of incubation, cells were stained with
P-iodonitrotetrazolium violet (1 mg ml') and colonies containing
more than 64 cells were counted under a microscope. Morphology
of colonies 4 days after cell seeding in soft agar was observed
under a phase-contrast microscope at 200 x magnification.
DNA probes
An EcoRI fragment of human N-ras cDNA (Taparowsky et al,
1983) was derived from the Japanese Collection of Research
Biosources-Gene (Tokyo, Japan). A PstI fragment of human
urokinase cDNA (Veder et al, 1984) was derived from the
American Type Culture Collection (ATCC; Rockville, MD, USA).
Northern blot analysis
Total RNA (10 lOtg) extracted from cells was denatured and
electrophoresed in 1.2% agarose gels containing 0.66 M formalde-
hyde. Hybridization was performed as described (Kondoh et al,
1992) using cDNA probes labelled with [32p] ox-dCTP by the
method of Feinberg and Vogelstein (1983). Specific hybridization
Nuclear run-on assay
A nuclear run-on assay was performed as described (Kondoh et al.
1991). Filters were blotted with 5 tg of PstI fragment of human
urokinase cDNA and 5 ,ug of BamHI/EcoRI fragment of human
cardiac actin DNA (Gunning et al, 1984). Specific hybridization
was visualized and band intensity was measured by the BAS-2000
image analysing system (Fuji Film, Tokyo, Japan).
RESULTS
Expression of PU.1 protein in PU.1-transfected HT1080
cells
To examine cell biological function of PU.1, we transfected a
pLRNL expression vector containing full-length mouse PU.
cDNA into a clone (NM-1) of PU.1-negative human fibrosarcoma
HTl080 cells. Four independent PU. -expressing HT 1080 NM-
clones were obtained and designated NMPU.1-7, NMPU.1-8-l,
NMPU.1-11-L and NMPU.1-26 respectively. Western blot
analysis using polyclonal antibody against PU.1 revealed that
NMPU.1-7 and NMPU.1-11-L cells expressed higher and the
highest levels of the protein, whereas NMPU. 1-8-1 and NMPU. 1-
26 cells expressed moderate and the lowest levels of the protein
respectively. No PU.1 protein was observed in parental HT1080
NM- l cells (Figure 1).
Cell biological features of PU.1-transfected HT1080
cells
We first examined the effect of ectopic expression of PU. on
growth properties ofHT1080 NM-1 cells. As shown in Table 1, we
found no substantial effect of PU. on the doubling time for prolif-
eration of NM- cells grown in the adherent culture. However,
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Figure 3 Expression of the PU. 1, N-ras and uPA genes in PU. 1-transfected HT1 080 NM-1 (A) and cl-2 (B) clones and mock-transfected clones (vector). Total
RNAs were extracted from the cells grown either in the absence (-) or presence (+) of 10-7 M DEX for 24 h. The ribosomal RNAs in agarose gels were stained
with ethidium bromide for an internal control of sample loading
when we examined growth of the cells in soft agar, we found a
significant reduction in colony formation in PU.]-transfected cells
compared with the control cells of parental and mock-transfected
NM-1 cells. The degree of reduction of colony-forming ability in
the transfectants seemed to be inversely correlated with the degree
ofthe levels ofPU. 1 protein in these cells (Table 1). Morphological
examination of soft-agar colonies at the early stage under a
microscope demonstrated that all the PU.I transfectants exhibited
colonies with cells sparsely distributed. By contrast, parental cells
and mock transfectants exhibited colonies with very limited cell
spreading in soft agars (Figure 2), suggesting that expression of
PU. 1 may increase migration of cells in soft agar. Representative
morphological appearances of the parental cells and a PU.I trans-
fectant (NMPU. 1-7) grown in soft agar are shown in Figure 2A and
B respectively. Other PU.I transfectants also exhibited similar
growing patterns to NMPU. 1-7 (data not shown). In spite of the
difference in growth patterns in soft agar, no particular morpho-
logical alterations were observed between PU.] transfectants and
the control cells grown in plastic culture plates (data not shown).
Expression of the uPA and N-ras genes in
PU.1-transfected HT1080 cells
It has been reported that the activated N-ras gene is crucial for
keeping the transformed phenotypes of HT1080 cells (Hall et al,
1983; Paterson et al, 1987) and that the elevated levels of expres-
sion of urokinase-type plasminogen activator (uPA) are associated
with cell migration and malignant transformation in several types
of tumour cells (Kirchheimer and Remold, 1989; Chambers et al,
1995). Therefore, we examined whether PU.1 could affect expres-
sion of these genes in HT1080 NM-l cells. As shown in Figure
3A, NMPU.1-7 and NMPU. 1-11-L cells expressed higher levels of
PU. I mRNA transcribed from the viral long terminal repeat (LTR)
in the expression vector (a 2-kb transcript and a 4-kb through-
reading transcript), NMPU.1-8-1 cells moderate level, and
NMPU.1-26 lower level. No expression of the PU.I gene was
observed in parental and mock-transfected NM- 1 cells. The levels
of PU.] mRNA were almost consistent with the protein levels
detected by Western blot analysis shown in Figure 1. Expression of
the N-ras oncogene was not markedly affected by ectopic expres-
sion of PU. 1 in NM-I cells. However, the steady-state levels of
uPA mRNA were significantly enhanced in all of the PU.I trans-
fectants compared with parental NM- 1 cells and a mock transfec-
tant (compare lanes 1 and 3 with lanes 5, 7, 9 and 11 in Figure 3A).
This was also true in another series of transfectants (LRPU. 1-6,
LRPU. 1-9, LRPU.1-14 and LRPU.1-15) established by trans-
fecting the PU.I expression vector into another HT1080 subclone,
cl-2 (compare lanes 1 and 3 with lanes 5, 7, 9 and 11 in Figure 3B).
Effect of glucocorticoid on uPA expression and cell
migration in HT1080 cells
It is certainly evident that synthetic glucocorticoids such as dex-
amethasone (DEX) act as suppressors of uPA at the transcriptional
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Figure 4 Nuclear run-on analysis of the uPA (U) and actin (A) genes in
mock-transfected (vector) and PU. 1-transfected LRPU.1-15 cells untreated
(-) or treated (+) with 10-7 of DEX for 24 h. The signal specific for the uPA
gene was compared as a ratio of the intensity with that of the actin gene used
as an internal control
level in HT1080 cells (Medcalf et al, 1986). Furthermore, tran-
scriptional interference between PU.1 and steroid/vitamin receptor
family members has been reported in vitro using the chloram-
phenicol acetyltransferase (CAT) assay (Gauthier et al, 1993).
Therefore, we examined whether expression of PU. I interferes
with the effect of DEX on uPA expression in vivo in HT1080 cells.
As shown in Figure 3A and B, treatment ofHT1080 cells and mock
transfectants with 10- M of DEX greatly reduced uPA mRNA
levels in these cells. Although a decrease in the level of uPA tran-
scripts was also observed in PU.l-transfected cells after treatment
with DEX, the levels were still higher than those in parental and
mock-transfected control cells without DEX treatment.
Densitometric analysis revealed that the levels were reduced to
80%, 62%, 73% and 40% in NMPU. 1-7, NMPU.1-8-1, NMPU.l-
1 -L and NMPU. 1-26 cells, whereas they were reduced to 40% and
50% in parental and mock-transfected NM-1 cells respectively
(Figure 3A). In the same context, DEX reduced the levels of uPA
mRNA to 60%, 33%, 55% and 87% in LRPU.1-6, LRPU.l-9,
LRPU.1-14 and LRPU.1-15 cells, but to less than 10% in control
cl-2 cells, respectively (Figure 3B). In contrast, DEX did not affect
N-ras gene expression in these PU.I-expressing cells as well as the
control cells. In HT1080 cells, DEX seemed to increase slightly
rather than decrease expression ofthe transfected PU.I gene. These
results indicate that DEX specifically reduced uPA expression in
HT1080 cells but the degree ofreduction was alleviated by expres-
sion ofthe PU.I gene.
The effect of DEX on growth properties of PU.I transfectants
was then examined. Neither cell growth in adherent culture nor
colony formation in soft agar of HT1080 cells was inhibited even
in the presence of DEX (data not shown). Microscopic examina-
tion of the colonies in soft agar showed that parental and mock-
transfected HT1080 NM-1 cells formed tight and more compact
confines without cell spreading in soft agar in the presence of
DEX compared with the colonies in the absence of DEX (compare
A with C in Figure 2). On the other hand, PU.I transfectants failed
to form compact colonies, although cell spreading was much
reduced in the presence ofDEX (compare C with D, and B with D
in Figure 2). These results suggest that DEX reduces cell motility
and/or enhances cell-cell adhesion and that ectopic expression of
PU.1 alleviates the effect of DEX in HT1080 cells.
Transcriptional and post-transcriptional control of the
uPA gene by ectopic expression of PU.1 and DEX
treatment in HT1080 cells
In order to examine whether the effects of PU.1 and DEX on uPA
expression occurred at the transcriptional level, a nuclear run-on
assay was performed using nuclei isolated from PU.I-transfected
and mock-transfected cells in the presence or absence of DEX.
LRPU.1-15 was chosen as a representative PU.I transfectant
because of the highest expression of uPA mRNA among the
isolated clones. A mock-transfected clone was used as a control. As
shown in Figure 4, the levels ofuPA transcription were very similar
in both cells, although the accumulation ofuPA mRNA was signif-
icantly higher in LRPU.1-15, compared with mock-transfected
cells. The levels of the actin transcription, examined as a control
gene, were almost the same between control and LRPU.1-15 cells.
Northern blot analysis demonstrated that levels of actin mRNA
were also unchanged between the two (data not shown). On the
other hand, the relative level of uPA transcription in mock-trans-
fected cells, as judged in comparison with the level of actin tran-
scription, was significantly reduced to 25% by DEX treatment,
whereas in LRPU.1-15 cells it was merely reduced to 88%. The
actin transcription was not reduced by DEX in both cells. These
results suggest that the transcription rate ofthe uPA gene was unaf-
fected by PU.1 in the absence of DEX and that increase in steady-
state level of uPA mRNA by PU.1 is mainly accounted for by
post-transcriptional control. Meanwhile, transcription of the uPA
gene was markedly reduced by DEX treatment. The negative effect
ofDEX on the uPA transcription was, however, significantly allevi-
ated by expression of PU.1 in HT1080 cells.
DISCUSSION
We found that exogenous expression of PU.l in HT1080 human
fibrosarcoma cells increased cell migration in soft agar. In associa-
tion with these cell biological changes, expression of the uPA
mRNA, which encodes a serine protease correlated with cell
migration and invasion, was enhanced in PU.l-transfected
HT1080 cells compared with mock transfectants. The uPA gene
has a transcriptional enhancer region, which consists of binding
sites for Fos/Jun family transcription factors AP-1 and an Ets
family transcription factor PEA3, and this region has been
reported to be critical for activation of the gene in HT1080 cells
(Nerlov et al, 1991). In murine macrophages, Ets-2 activates the
uPA enhancer by binding to the PEA3 site, whereas other Ets
family transcription factors such as PU. I and PEA3 do not activate
the enhancer (Stacey et al, 1995). To examine whether purified
PU.1 protein or that in a crude nuclear extract from LRPU.1-15
cells can bind to the PEA3 site, we performed an electrophoretic
mobility shift assay. However, PU.1 did not bind to this site (data
not shown), suggesting that PU.1 cannot directly affect the
enhancer region ofthe uPA gene through the PEA3 site within this
region. Furthermore, run-on analysis demonstrated that PU. I did
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not affect uPA gene expression at the transcriptional level in
HT1080 cells. Therefore, the accumulation of the uPA mRNA in
PU. ]-transfected cells may be due to the post-transcriptional
mechanism(s), perhaps by increasing the uPA mRNA stability in
the cells. There are several reports demonstrating post-transcrip-
tional regulation of uPA gene; in rat fibroblasts uPA gene expres-
sion is post-transcriptionally suppressed compared with highly
metastatic carcinoma cells (Henderson et al, 1991, 1992); uPA
mRNA stability is specifically increased by a synergistic effect of
Ca2+ and cAMP in renal epithelial cells (Altus et al, 1987, 1991;
Zeigler et al, 1990); and cycloheximide, an inhibitor of protein
synthesis, increases the uPA mRNA half-life from 70 min to >20 h
(Altus et al, 1991). Therefore, there may be a protein(s) of short-
half life, potentially attaching to the A+U-rich elements in the 3'-
untranslated region ofthe uPA mRNA and responsible for specific
degradation of the mRNA (Altus et al, 1991; Henderson and
Kefford 1991). PU. I may affect the level and/or function of such
proteins.
There are several reports showing that glucocorticoid can lower
uPA activity in a number of cell types (Littlefield et al, 1985;
Medcalf et al, 1986). Consistent with previous reports by others
(Medcalf et al, 1986), our results suggest that the suppression of
the uPA gene expression by DEX occurs at the transcriptional level
in HT1080 cells. Furthermore, we demonstrate that DEX antago-
nized the effect of PU. I on morphology of colonies grown in soft
agar: PU.I stimulated cell migration, whereas DEX inhibited it. In
parallel with this, PU.1 alleviated the negative effect of DEX on
uPA expression at the transcriptional level in HT1080 cells. It has
been reported that the glucocorticoid receptor (GR) interferes with
the function of PU.1 and vice versa in human breast cancer cells
(Gauthier et al, 1993). Similar mutual functional interference
between Fli-1, another ETS family protein, and steroid hormone
receptors was also reported recently (Darby et al, 1997).
Therefore, our observation may be accounted for by such a func-
tional interference, by which PU.I blocks the transcriptional
suppressing activity ofGR in HT1080 cells.
We also found that PU. 1 brought about negative effects upon the
anchorage-independent growth of HT1080 cells: the PU.] trans-
fectants exhibited reduced colony formation in soft agar. Similar
observations have been reported in some tumours: constitutive
expression of Ets-1 reverts the tumorigenicity in human colon
cancer cells (Suzuki et al, 1996) and stable expression of a trans-
dominant mutant of PU.1 or Ets-2 also reverts Ras-transformed
NIH/3T3 cells (Langer et al, 1992; Wasylyk et al, 1994). It is
known that HT1080 cells harbour the activated N-ras oncogene,
which is essential for maintaining the transformed phenotypes of
the cells, and inhibition of N-ras gene expression rendered the
cells less malignant (Hall et al, 1983; Paterson et al, 1987).
However, PU.1-transfected HT1080 cells expressed similar levels
of N-ras mRNA to the parental cells and mock transfectants
(Figure 3A and B). As a member of the Ets family proteins is one
of the nuclear targets of the ras signalling pathway to activate ras-
responsive elements (Wasylyk et al, 1990; Galang et al, 1994), the
ectopic expression of PU. I may perturb endogenous Ets family
proteins, which mediate the ras signals crucial for maintenance of
the transformed phenotypes of HT1080 cells.
In conclusion, our results could provide an insight into a novel
function of Ets-related transcription factor PU.I on several
transformed phenotypes provoked, in part, by the activated N-ras
oncogene.
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